Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Infusion of CD30 CAR T-cells following AuHCT in patients with lymphoma

Marcie Riches • 15 Feb 2021
TCT 2021
Hodgkin Lymphoma Lymphoma

Marcie Riches, MD, MS, The University of North Carolina at Chapel Hill, Chapel Hill, NC, discusses the results of a Phase I multicenter study evaluating the use of CD30 CAR T-cell infusion following autologous transplant (AuHCT) in patients with relapsed/refractory lymphoma. The results of this study demonstrate CD30 CAR-T infusion is safe and well-tolerated, with a 1-year progression-free survival of 79% in patients with Hodgkin lymphoma. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Marcie Riches

3:10
The CIBMTR COVID-19 experience
Marcie Riches • 15 Feb 2021
2:23
Highlights from TCT 2021: microbiome & impact of COVID-19
Marcie Riches • 15 Feb 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals